Late side-effects of stem cell transplantation include hypogonadism with infertility and sexual dysfunction, but gynaecomastia is less well recognised. We report five cases of gynaecomastia with features of hypergonadotrophic hypogonadism (primary testicular failure), who received either a TBI/cyclophosphamide conditioned allograft (n = 3) or a BEAM autograft (n = 2). Patients receiving an allograft had gynaecomastia, Leydig cell insufficiency (LCI) diminished libido and erectile dysfunction. Surgery was required in one case, while in two cases the gynaecomastia resolved spontaneously after 6 months. Two patients also had gynaecomastia and sexual dysfunction, severe hypogonadism, very low testosterone levels and marked hyperprolactinaemia following autoBMT. Both responded well to testosterone replacement therapy (TRT). As a group, all patients had primary testicular failure and all except one, had LCI (compensated or frank). However, there was no correlation between the severity of gynaecomastia and the degree of endocrine dysfunction. This preliminary study is the first to suggest that gynaecomastia, due to primary hypogonadism and LCI, may be a significant complication of myeloablative conditioning therapy. Therefore gynaecomastia in BMT recipients must always be treated as a pathological entity as it may be the external manifestation of a complex endocrine pathology. It is a potentially treatable condition. Although spontaneously reversible, some patients may require TRT or even surgery. We recommend comprehensive endocrine testing in conjunction with a reproductive endocrinologist and prompt intervention to alleviate embarrassment and anxiety in afflicted BMT recipients. Bone Marrow Transplantation (2001Transplantation ( ) 28, 1141Transplantation ( -1144 
Improvements in bone marrow transplant (BMT) techniques have led to an increase in numbers of long-term survivors. With this comes the need for increased awareness of long-term effects including hypogonadism with concomitant sexual dysfunction and infertility, which may only become apparent months or even years after transplantation but affect the quality of life of survivors, especially the young adults. 1 Testicular damage is an invariable effect of high-dose chemotherapy (H-D CT) or chemoradiotherapy (H-D CRT), primarily due to direct insult to the germ cells and Leydig cells. We have previously shown that there is a 50% reduction in testicular volume following H-D CRT, with concomitant elevation in gonadotrophins, analogous to functional castration. 2 However, hypopituitarism with secondary hypogonadism and hyperprolactinaemia is a well-recognised feature in recipients of total body irradiation (TBI). 3, 4 The most common symptom of hypogonadism is diminished libido and erectile dysfunction (ED). However, gynaecomastia may also be a presenting feature. When it occurs it may cause significant physical symptoms and psychological problems. There are no previously published data concerning gynaecomastia in the bone marrow transplant setting. The incidence is unknown. In a recent large retrospective study of 117 recipients of BMT for haematological malignancies, we looked at gonadal function immediately prior to and 3-18 months post BMT. 5 None of the patients presented with gynaecomastia in this large group of BMT recipients. It is therefore tempting to speculate that gynaecomastia is a rare problem and was absent in all our patients. However, it is impossible to rule out the possibility of transient gynaecomastia which may have occurred in some patients prior to their referral to the reproductive endocrine clinic.
The incidence of active gynaecomastia in 5-9% of the general population is derived from autopsy data. 6 However, this may be an underestimate of the true incidence. At least one study 7 suggests that up to 40% of normal men have gynaecomastia, which may also be an overestimate. Since hypogonadism is a common feature in BMT recipients, gynaecomastia is likely to be a common entity, and is probably underdiagnosed and poorly reported. This may be partly due to a transient clinical picture or failure of patients to report this to clinicians due to embarrassment and poor esteem. Also, the complex endocrine pathophysiology of gynaecomastia makes the diagnosis a difficult one to make for conventional haemato-oncologists dedicated to the care of the BMT recipients.
In many cases, it may be transient and resolve spontaneously, but if gynaecomastia persists, appropriate medical or surgical intervention may be required. A comprehensive endocrine assessment is important to establish the cause and best approach to treatment.
The aim of this study was to determine the cause(s) of gynaecomastia and to formulate the best management options in a small cohort of recipients of BMT presenting with gynaecomastia.
Patients and methods
In a retrospective observational study, we evaluated five patients aged 22-56 years, who had undergone either a sibling allogeneic BMT conditioned with cyclophosphamide (120 mg/kg)/total body irradiation (1440 cGy) for leukaemia (patients 1, 2 and 3) or a BEAM-autograft (BCNU 300 mg/m Libido and erectile dysfunction were recorded using the questionnaire method. 8 All patients had assessment of testicular volume, scalp and pubic body hair. 8 Gynaecomastia was assessed by Simon's classification based on breast volume and skin redundancy. 9 Pituitary testicular function was determined by testicular volume (orchidometry and ultrasound where feasible), 8 and endocrine profile (follicle stimulating hormone (FSH), luteinising hormone (LH), testosterone (T) (total and free percentage)). Adrenal androgen production was measured using androstenedione (A) and dehydroepiandrosterone-sulphate (DHEAS). Free thyroxine, thyroid stimulating hormone (TSH), prolactin, sex hormone binding globulin (SHBG) and oestradiol-17-␤ (E2) levels were also measured.
Leydig cell insufficiency (LCI)
Leydig cell insufficiency was defined as frank (LH Ͼ10 IU/l and T Ͻ10 nmol/l) and compensated (LH Ͼ10 IU/l and T Ͼ10 nmol/l with T/LH ratio Ͻ2) according to our recently published data. 5 
Blood sampling and hormone assays
Blood sampling was undertaken at 0800-0900 h to minimise episodic and diurnal fluctuations of the hormones.
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However, we appreciate that unless an intensified blood sampling protocol is undertaken, it is impossible to get the most accurate result of hormones from single base line samples. 12 All hormones were assayed by radioimmunoassays using double antibody technique and in-house methods, by the same observer (HHM). 13 
TRT
Patients 3, 4 and 5 had a short therapeutic trial of testosterone replacement therapy (TRT) for 3-6 months in the form of depotestosterone cypionate (intramuscular injection of sustenon 250 mg at monthly interval). Tables 1 and 2 show the patient physical characteristics and endocrine investigations, respectively. All patients except one (patient 2) had hypergonadotrophic hypogonadism, as well as symptoms of Leydig cell insufficiency (LCI), including diminished libido, erectile dysfunction and a variable degree of gynaecomastia. All except one (patient 2) had diminished LC reserve with compensated LCI as evident from a diminished testosterone/LH (T/LH) ratio.
Results
Patient 1 presented with grade 1 gynaecomastia and diminished libido, as well as erectile dysfunction. He had hypogonadism (testicular volume 10-12 ml, elevated FSH), compensated Leydig cell insufficiency (normal testosterone with high LH levels and low T/LH ratio), low adrenal androgen DHEA. Gynaecomastia resolved in 6 months.
Patient 2 presented with grade 1 gynaecomastia. He also had hypogonadism (testicular volume 10 ml) without LCI. He had elevated serum oestradiol levels, but normal percentage of free testosterone. Gynaecomastia resolved in 6 months.
Patient 3 presented with grade 3 gynaecomastia, scanty facial and body hair and diminished libido. He had hypogonadism (testicular volume 10 ml), elevated gonadotrophins, low total as well as percentage of free testosterone levels with low T/LH ratio, diminished DHEA levels and hyperprolactinaemia. He did not respond to TRT, but responded well to mastectomy.
Patient 4 presented with grade 1 gynaecomastia and features of LCI, such as diminished libido and erectile dysfunction (ED). He had severe primary hypogonadism (testicular volume 2-4 ml), low testosterone levels, T/LH ratio, and hyperprolactinaemia. He responded well to TRT, which corrected libido, ED and gynaecomastia within 3 months. Patient 5 presented with grade 1 gynaecomastia and sexual dysfunction. He had primary hypogonadism (testicular volume 8-10 ml), high FSH levels and compensated Leydig cell insufficiency with reduced T/LH ratio, percentage of free testosterone, but normal oestradiol levels. His gynaecomastia and sexual dysfunction resolved within 3 months of starting TRT.
Discussion
The results of this study suggest that gynaecomastia was a distressing problem in five BMT recipients. Although it may resolve spontaneously, and appears to be an uncommon condition in recipients of high-dose chemotherapy/chemo-radiotherapy, it is not a physiological condition. Apart from the three well-described physiological causes of gynaecomastia, which include being newborn, pubertal or ageing, gynaecomastia is usually considered to be a pathological entity.
14 Three cardinal mechanisms held responsible for gynaecomastia may hold good for BMT recipients too. They include (1) deficiency in neither production or action of testosterone without a secondary rise in oestrogen; (2) increase in serum oestradiol levels from elevated gonadotrophin secretion, increased peripheral conversion of oestradiol from androgens, or increased aromatase enzyme; (3) iatrogenic or due to drugs. It seems logical to suggest that primary testicular failure with hypergonadotrophism is one of the leading causes of gynaecomastia in our patients as all five of these patients showed evidence of primary hypogonadism with reduced testicular volume and elevated FSH. They also had symptomatic Leydig cell insufficiency as reflected by high LH and low or normal testosterone levels, with diminished libido and erectile dysfunction. Hypergonadotrophic hypogonadism with LCI is a well-recognised endocrinopathy, as evident from our large study, 5 as well as others. 1 The gonadotrophin theory of gynaecomastia is in accordance with other diseases such as bronchogenic carcinoma, Sertoli cell tumours and many other conditions, where there is increased production of HCG or other gonadotrophins. 14, 15 Although the exact mechanism of gonadotrophin induced gynaecomastia is unknown, it is stated that gonadotrophins probably induce oestrogen-like activity similar to drugs such as digitalis. 15 Secondary hypogonadism due to hyperprolactinaemia and hypothalamic-pituitary dysfunction may act, at least as a facilitating factor, in the aetiology of gynaecomastia. This is especially applicable to TBI recipients, as evident from our previous study, 3 as well as others. 4 Persistent hyperprolactinaemia was present in two patients (Nos 3 and 4) . One of whom (patient 3) had received TBI. Another patient had a BEAM autograft for lymphoma. Although similar reports are not available with BEAM, gynaecomastia is reported in patients who had received alkylating agents 15 or other chemotherapy. 16 Hyperprolactinaemia is an established
Bone Marrow Transplantation cause of gynaecomastia due to other diseases including hypo/hyperthyroidism. 17 However, thyroid dysfunction was not contributory to the gynaecomastia in our patients as all of them had normal thyroid function tests.
Drugs including histamine (H2) blockers, such as cimetidine and ranitidine, are noted to be associated with sexual dysfunction and gynaecomastia. 15 Cimetidine blocks testosterone synthesis and increases oestradiol level by inhibiting its 2-hydroxylation. 18 Ranitidine does not block androgens or induce hypergonadotrophism. However, inhibition of liver-cytochrome p-450, which inhibits the oxidative metabolism of oestradiol, is postulated as a mechanism. 19 It is well known that adrenal androgens such as DHEA are weak androgens and per se are unlikely to contribute to hypoandrogenism and gynaecomastia and/or sexual dysfunction. However, low DHEA levels may play an important facilitating role in our BMT recipients with sexual dysfunction, as a recent double-blind, randomised, placebo-controlled prospective study has shown the use of DHEA in the treatment of patients with erectile dysfunction. 20 Adrenal suppression by cortocosteroids may also cause a reduction in DHEA levels. 15 Patient 3 had not received steroids at the time of presenting with gynaecomastia, but subsequently received high-dose steroids for graftversus-host disease. This may have contributed to the persistence of his gynaecomastia. Cyclosporin, received by patients 1-3, can cause transient breast enlargement through altered target organ sensitivity, but if it does so, it is always concurrent with hypertrichosis (not hirsutism). None of the patients had hypertrichosis and we do not consider cyclosporin to be relevant hormonally in this report.
Although androgen/oestrogen (A/E) imbalance was not evident from the endogenous circulating endocrine data, this may occur at a tissue level where breast tissue becomes sensitive to oestrogen action. This is cited as one of the mechanisms of gynaecomastia in ageing 14 or drug-induced gynaecomastia 15 or in diseases including bronchogenic carcinoma with increased HCG levels. 15 Similar mechanisms are likely to be held responsible for gynaecomastia in BMT recipients who have target organ resistance as demonstrated by compensated LCI with elevated gonadotrophin levels.
Thus, TRT is useful to correct A/E imbalance at an end organ level. TRT was feasible in four of five patients. This is consistent with the established mode of treatment of gynaecomastia. 21 Another advantage of TRT in symptomatic LCI patients is its ability to induce cavernosal vasodilator activity. 22 Since BMT recipients may have cavernosa arterial insufficiency, as well as hypogonadism, 8 TRT may have additional advantages, including improvement in libido and nocturnal tumescence, as well as erectile performance. 23 Only one patient needed surgical intervention. This is in agreement with the literature that surgery is seldom needed in the management of gynaecomastia. 24, 25 In conclusion, this is the first report to document gynaecomastia in BMT recipients. Gynaecomastia may be a distressing symptom associated with sexual dysfunction. It is multifactorial in origin. Primary testicular failure with hypergonadotrophic hypogonadism is likely to be the key cause, although other factors such as secondary hypogonadism with hyperprolactinaemia, drug-induced gynaecomastia with target organ insensitivity and H2 blockers may be contributory factors. As more bone marrow transplants are being performed and patients are living longer, more cases of gynaecomastia will undoubtedly be reported. It can cause significant physical symptoms and psychosocial problems for the patient. Although some cases may resolve spontaneously, gynaecomastia in BMT recipients must be considered as a pathological condition. A full endocrine evaluation should be undertaken to find the cause(s) for the gynaecomastia and to allow a treatment strategy to be formulated. TRT must be considered as first-line therapy for gynaecomastia as these patients also have symptomatic LCI, including diminished libido and erectile dysfunction. Surgery should be reserved for the refractory cases.
